Market Overview

UPDATE: Wedbush Initiates Epizyme at Outperform on Therapeutics Targeting HMTs


In a report published on Wednesday, Wedbush analyst Gregory R. Wade initiated coverage on Epizyme (NASDAQ: EPZM) with an Outperform rating and a $37 price target.

In the report, Wedbush stated, "Advances in genetically defining sub-sets of cancer patients have identified members of the family of histone methyltransferase (HMT) proteins as key drivers of malignancy. EPZM's small molecule drug discovery platform seeks to marry the appropriate HMT antagonist with the genetically definable malignancy."

Epizyme closed on Wednesday at $26.96.

Latest Ratings for EPZM

Dec 2020JefferiesDowngradesBuyHold
Nov 2020Morgan StanleyMaintainsOverweight
Aug 2020Morgan StanleyMaintainsOverweight

View More Analyst Ratings for EPZM
View the Latest Analyst Ratings


Related Articles (EPZM)

View Comments and Join the Discussion!

Posted-In: Gregory R. Wade WedbushAnalyst Color Initiation Analyst Ratings

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at